Intervacc AB (publ) (IVACC.ST)
SEK 2.38
(4.39%)
SEK 2.38
(4.39%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 10.48 Million SEK | -57.04% |
| 2022 | 24.4 Million SEK | 1457.37% |
| 2021 | 1.56 Million SEK | 4.75% |
| 2020 | 1.49 Million SEK | 26.14% |
| 2019 | 1.18 Million SEK | -89.09% |
| 2018 | 10.86 Million SEK | -37.24% |
| 2017 | 17.31 Million SEK | -12.18% |
| 2016 | 19.71 Million SEK | 20.37% |
| 2015 | 16.37 Million SEK | 33.86% |
| 2014 | 12.23 Million SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 11.69 Million SEK | 17.34% |
| 2024 Q1 | 9.96 Million SEK | -4.94% |
| 2023 Q2 | 28.23 Million SEK | 1.06% |
| 2023 FY | 10.48 Million SEK | -57.04% |
| 2023 Q4 | 10.48 Million SEK | -5.52% |
| 2023 Q1 | 27.93 Million SEK | 14.49% |
| 2023 Q3 | 11.09 Million SEK | -60.7% |
| 2022 Q3 | 33.03 Million SEK | 32.42% |
| 2022 Q1 | 15.05 Million SEK | 860.69% |
| 2022 FY | 24.4 Million SEK | 1457.37% |
| 2022 Q2 | 24.94 Million SEK | 65.73% |
| 2022 Q4 | 24.4 Million SEK | -26.13% |
| 2021 FY | 1.56 Million SEK | 4.75% |
| 2021 Q1 | 1.4 Million SEK | -6.35% |
| 2021 Q4 | 1.56 Million SEK | -67.12% |
| 2021 Q3 | 4.76 Million SEK | 152.44% |
| 2021 Q2 | 1.88 Million SEK | 34.76% |
| 2020 Q2 | 777 Thousand SEK | -24.64% |
| 2020 Q1 | 1.03 Million SEK | -13.07% |
| 2020 Q3 | 1.23 Million SEK | 59.2% |
| 2020 FY | 1.49 Million SEK | 26.14% |
| 2020 Q4 | 1.49 Million SEK | 20.94% |
| 2019 FY | 1.18 Million SEK | -89.09% |
| 2019 Q2 | 2.13 Million SEK | -58.57% |
| 2019 Q4 | 1.18 Million SEK | -20.93% |
| 2019 Q3 | 1.5 Million SEK | -29.74% |
| 2019 Q1 | 5.15 Million SEK | -52.58% |
| 2018 Q2 | 16.6 Million SEK | 5.07% |
| 2018 FY | 10.86 Million SEK | -37.24% |
| 2018 Q4 | 10.86 Million SEK | -14.26% |
| 2018 Q3 | 12.67 Million SEK | -23.68% |
| 2018 Q1 | 15.8 Million SEK | -8.71% |
| 2017 Q3 | 17.06 Million SEK | -25.2% |
| 2017 Q4 | 17.31 Million SEK | 1.44% |
| 2017 FY | 17.31 Million SEK | -12.18% |
| 2017 Q1 | 13.09 Million SEK | -33.6% |
| 2017 Q2 | 22.81 Million SEK | 74.31% |
| 2016 Q4 | 19.71 Million SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | 19.71 Million SEK | 20.37% |
| 2015 FY | 16.37 Million SEK | 33.86% |
| 2014 FY | 12.23 Million SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 2.00 SEK | -524149900.0% |
| Ziccum AB (publ) | -4.18 Million SEK | 350.251% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | - SEK | -Infinity% |
| Sprint Bioscience AB (publ) | -7.13 Million SEK | 246.903% |
| Mendus AB (publ) | - SEK | -Infinity% |
| Genovis AB (publ.) | 14.9 Million SEK | 29.668% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | - SEK | -Infinity% |
| Active Biotech AB (publ) | -2500.00 SEK | 419420.0% |
| Magle Chemoswed Holding AB (publ) | 35.22 Million SEK | 70.243% |
| Bio-Works Technologies AB (publ) | 9.06 Million SEK | -15.604% |
| Aptahem AB (publ) | - SEK | -Infinity% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | -1950.00 SEK | 537689.744% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | 3.15 Million SEK | -232.794% |
| Saniona AB (publ) | 1.00 SEK | -1048299900.0% |
| Lipigon Pharmaceuticals AB (publ) | -1.62 Million SEK | 744.711% |
| Biovica International AB (publ) | 2.19 Million SEK | -376.717% |
| Spago Nanomedical AB (publ) | 1.00 SEK | -1048299900.0% |
| AcouSort AB (publ) | 2.08 Million SEK | -403.99% |
| Xintela AB (publ) | 398 Thousand SEK | -2533.92% |
| Abliva AB (publ) | - SEK | -Infinity% |
| Egetis Therapeutics AB (publ) | 700 Thousand SEK | -1397.571% |
| Karolinska Development AB (publ) | - SEK | -Infinity% |
| OncoZenge AB (publ) | -862.99 Thousand SEK | 1314.718% |
| Amniotics AB (publ) | 534 Thousand SEK | -1863.109% |
| 2cureX AB (publ) | -1000.00 SEK | 1048400.0% |
| CombiGene AB (publ) | -1.79 Million SEK | 682.713% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 20.42 Million SEK | 48.683% |
| Camurus AB (publ) | 100.95 Million SEK | 89.616% |
| Corline Biomedical AB | -3.85 Million SEK | 371.792% |
| IRLAB Therapeutics AB (publ) | 1000.00 SEK | -1048200.0% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | 4.28 Million SEK | -144.93% |
| Hansa Biopharma AB (publ) | 9.79 Million SEK | -7.057% |
| Cyxone AB (publ) | - SEK | -Infinity% |
| ExpreS2ion Biotech Holding AB (publ) | - SEK | -Infinity% |
| Biosergen AB | -4.92 Million SEK | 312.68% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 545.23 Thousand SEK | -1822.65% |
| Xspray Pharma AB (publ) | 43.78 Million SEK | 76.056% |
| Elicera Therapeutics AB (publ) | -446.98 Thousand SEK | 2445.264% |
| Nanologica AB (publ) | 2.97 Million SEK | -252.607% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | -321.14 Thousand SEK | 3364.258% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | - SEK | -Infinity% |
| BioInvent International AB (publ) | 11.84 Million SEK | 11.491% |
| Alzinova AB (publ) | -3.27 Million SEK | 419.799% |
| Oncopeptides AB (publ) | 2.42 Million SEK | -332.289% |
| Pila Pharma AB (publ) | 1.00 SEK | -1048299900.0% |
| Guard Therapeutics International AB (publ) | -1486.00 SEK | 705550.875% |
| Scandinavian ChemoTech AB (publ) | 4.03 Million SEK | -159.866% |
| Simris Alg AB (publ) | 1.09 Million SEK | -860.862% |
| Diamyd Medical AB (publ) | 24.05 Million SEK | 56.412% |
| Xbrane Biopharma AB (publ) | 106.85 Million SEK | 90.19% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 1.02 Million SEK | -919.747% |